Tourmaline Bio

Interleukin-6 (IL-6) is a powerful cytokine involved in a wide range of immune responses and is crucial in the body's defense mechanisms. While essential for our health, excessive levels of IL-6 have been linked to the pathology of numerous diseases, including autoimmune, inflammatory, and cardiovascular diseases. Given its central role in inflammation and disease progression, targeting IL-6 offers a promising avenue for developing new treatments that may significantly improve outcomes for patients with life-altering immune and inflammatory diseases. Learn more about how we are targeting IL-6 with our lead candidate, TOUR006: https://bit.ly/45ZVnNf    #biotechnology #eyehealth #drugdevelopment 

Thyroid eye disease (TED) is a complex autoimmune disorder where the immune system mistakenly attacks the tissues around the eyes, causing swelling, bulging, and pain.  Advances in our understanding of TED's pathogenesis have identified that inflammatory pathways are at the core of the disease, leading to research into novel therapies that offer the potential for better patient outcomes. Learn more about our lead candidate, TOUR006, and how it’s targeting underlying inflammatory pathways and being investigated as a potential new way to treat thyroid eye disease:  https://bit.ly/4eD5Ku1  #biotechnology #eyehealth #drugdevelopment 

Tourmaline announced today that Ryan Robinson, CPA, has been promoted to Chief Financial Officer and Treasurer. With nearly 15 years of finance and operations experience within the biotech industry, Ryan has been instrumental in our rapid growth over the last year as we continue to realize the 'pipelines in a product' potential of TOUR006. Read today's announcement: https://bit.ly/3W1BL82 #leadership #business #finance

Great news! Tourmaline Bio is set to join the Russell 2000® Index and the broad-market Russell 3000® Index on June 28th as part of the Russell indexes annual reconstitution. #RussellRecon #Russell2000 #Russell3000

Last week, the Tourmaline team stepped out to catch the Mets' game against the Dodgers prior to our Nasdaq bell ringing – a great night shared with our employees and board members! #teamwork #culture #tourmalinedreamteam

I’m happy to share that we are hiring at Tourmaline Bio for a Senior Manager / Associate Director, Medical Affairs Operations! Come join an exciting new medical affairs team in a great organization! Feel free to reach out with any questions. https://lnkd.in/ev4Gr6u2

Today at the Jefferies Global Healthcare Conference, Tourmaline Bio's CEO, Sandeep Kulkarni sat down with Roger Song to discuss the clinical progress of Tourmaline’s lead candidate, TOUR006, for the treatment of thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD). With many patients still at high risk of adverse cardiovascular events and a pressing need for safer, more patient-friendly treatments for TED, we are targeting a critical and unaddressed pathway of inflammation as we endeavor to develop solutions that truly matter. It was a pleasure sharing how Tourmaline Bio is innovating to address these critical areas. Stay tuned for more, as we continue in our efforts to lead the translation of immunological insights into clinical breakthroughs. Watch the webcast here: https://bit.ly/4bFp5Jc  #TourmalineBio #HealthcareInnovation #ClinicalTrials

ICYMI: Last week was one for the books, as Tourmaline Bio was honored to ring the closing bell on Nasdaq ($TRML). We are thankful for the tireless effort and passion of every team member committed to our vision of filling critical gaps in treatment for immune and inflammatory diseases with high unmet needs. This journey fills us with pride, and together we are excited to continue pushing the boundaries of innovation. #NASDAQ #DrugDiscovery #Healthcare

Yesterday, we rang the closing bell on Nasdaq surrounded by our exceptional team that has shown an unwavering commitment to our mission of creating a best-in-class medication that can truly make a difference in the lives of patients worldwide. We are incredibly proud of what we have built together and look forward to sharing many more successes in the future as we advance our mission to create impactful medicines for diseases where there is a high unmet need. #NASDAQ #Innovation #Healthcare

Tourmaline Bio is addressing a significant unmet medical need by targeting inflammation to develop best-in-class therapies for a wide range of immune and inflammatory diseases. Today, we are thrilled to ring today’s closing bell on the Nasdaq ($TRML) as we continue our journey to develop transformative medicines that dramatically improve patients' lives. Learn more: https://bit.ly/3X0O4C8 #NASDAQ #Innovation #Healthcare